Market Place
Sourcing Support
Genprex Secures U.S. Patent for Reqorsa in PD-L1-Positive Cancers
18 Nov 2025 //
PR NEWSWIRE
Genprex CEO Ryan to Present at 2025 Investor Summit Virtual
10 Sep 2025 //
PHARMAWEB
Genprex Plans to Launch New Company for Gene Therapy in Type-1 and 2 Diabetes
04 Sep 2024 //
PR NEWSWIRE
Vimgreen Completes Enrollment For Parkinson`s Disease Phase 2 Trial
15 Aug 2024 //
PR NEWSWIRE
Genprex Announces Positive Updates From Acclaim-1 And Acclaim-3 Trials
14 Aug 2024 //
PR NEWSWIRE
Genprex Gets Singapore Patent For Reqorsa With PD-1 Antibodies
13 Aug 2024 //
PR NEWSWIRE
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa
12 Mar 2024 //
PR NEWSWIRE
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
31 Jan 2024 //
PR NEWSWIRE
Genprex advances to Phase II expansion portion of Acclaim-1 trial
31 May 2023 //
CLINICAL TRIALS ARENA
Genprex Strengthens Therapy Program with License from University of Pittsburgh
15 Dec 2022 //
PRNEWSWIRE
Genprex Receives Approval to Proceed PI Trial of REQORSA with Tagrisso
14 Dec 2022 //
PRNEWSWIRE
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
16 Aug 2022 //
CLINICALTRIALSARENA
Genprex pairs gene therapy delivery tech with Keytruda in trial
06 Apr 2022 //
FIERCEPHARMA
Genprex Begins Dosing in Phase 1/2 Acclaim-1 Trial of REQORSA Immunogene Therapy
02 Mar 2022 //
BUSINESSWIRE
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX in Colon Cancer
27 Jan 2022 //
BUSINESSWIRE
Genprex Receives FDA FTD for REQORSA Immunogene Therapy + Keytruda in NSCLC
03 Jan 2022 //
BUSINESSWIRE
Genprex Announces Start of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™
23 Jun 2021 //
BUSINESSWIRE
Genprex In-Licenses Additional Gene Therapy Technologies for of Lung Cancer
06 May 2021 //
BUSINESSWIRE
Genprex In-Licenses Additional Gene Therapy Technologies
06 May 2021 //
BUSINESSWIRE
Genprex Announces Centralized Institutional Review Board Approval
05 May 2021 //
PRESS RELEASE
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene
13 Apr 2021 //
BUSINESSWIRE
Genprex Collaborators Report Positive Preclinical Data for REQORSA™
13 Apr 2021 //
BIOSACE
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy
30 Mar 2021 //
BUSINESSWIRE
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy
30 Mar 2021 //
BUSINESSWIRE
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow
21 Jan 2021 //
BUSINESSWIRE
Genprex Achieves Major Manufacturing Milestone for REQORSA™
13 Jan 2021 //
BIOSPACE
Genprex Completes Manufacturing Scale-Up for Clinical-Grade of REQORSA™
22 Dec 2020 //
BIOSPACE
Genprex Completes Manufacturing Scale-Up for Clinical-Grade of REQORSA™
22 Dec 2020 //
BIOSPACE
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
08 Dec 2020 //
BUSINESSWIRE
Genprex completes tech transfer for gene therapy to manufacturing
08 Dec 2020 //
SCIENCEBOARD
Genprex to Present at the Benzinga Global Small Cap Conference on December 8
03 Dec 2020 //
BUSINESSWIRE
Genprex Unveils New Branding for Upcoming Combination Clinical Trials
30 Oct 2020 //
BUSINESSWIRE
Genprex Unveils New Branding for Upcoming Combination Clinical Trials in NSCLC
30 Oct 2020 //
BUSINESSWIRE
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™
29 Oct 2020 //
GENPREX
Genprex to Present at Zooming with LD Micro on October 14, 2020
07 Oct 2020 //
BUSINESSWIRE
Genprex to Present at the ARM’s Virtual Cell and Gene Meeting on the Mesa
06 Oct 2020 //
BUSINESSWIRE
Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
30 Jul 2020 //
BUSINESSWIRE
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
25 Jun 2020 //
BUSINESSWIRE
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
24 Jun 2020 //
BUSINESSWIRE
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™
16 Jun 2020 //
BUSINESSWIRE
Genprex Expands Manufacturing Program with Aldevron to Oncoprex™ Development
16 Jun 2020 //
BUSINESSWIRE
Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
28 May 2020 //
BUSINESSWIRE
